Advertisement

Side Effects of Nociceptive Cancer Pain Treatments in Adults

  • Ivan Krakowski
  • Aline Henry
Chapter

Abstract

Pain is unfortunately a frequent symptom of cancer, especially in the advanced stages of disease. Its treatment must be integrated into a comprehensive supportive care approach, which itself must be conducted in parallel with specific therapeutic cancer agents, if indicated, and then integrated into the process of palliative care in the advanced phase.

Several classes of pain killers are available:
  • Nociceptive pain medications use non-opioid analgesics, weak opioids, and strong opioids, described in the three levels of the WHO ladder.

  • “Pure” neuropathic pain is treated by different drug classes, at least in the front line, such as antidepressants, antiepileptics, and some anesthetics such as ketamine. The analgesics in the WHO ladder, including opioids, are generally less effective for this indication, but they, as well as nondrug treatments, will be tried in case of refractory pain.

For the two types of pain, analgesics are often used in combination with co-analgesics (anxiolytics, corticosteroids, anti-osteoclast inhibitors, antispasmodics, etc.).

It is obviously important to know the main side effects of these different drug classes, in order to prevent them, to inform patients of their possible occurrence, and thereby to promote better compliance. The problem of compliance is indeed particularly acute in the area of pain therapy because patients want to use pain as an indicator of a possible disease progression or of an expected response to specific treatments of cancer, and they fear the side effects of analgesics in general and opioids in particular. The main side effects of analgesics are discussed in this chapter.

Keywords

Cancer Pain Side effect Pain killer Analgesic 

References

  1. 1.
    Dault RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer. 1982;50:1913–8.CrossRefGoogle Scholar
  2. 2.
    Van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–49.CrossRefPubMedGoogle Scholar
  3. 3.
    Bonica JJ, editor. The management of pain. 2nd ed. Philadelphia: Lea & Febiger; 1990.Google Scholar
  4. 4.
    Bouhassira D, Luporsi E, Krakowski I. Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer. Pain. 2017;158(6):1118–25.  https://doi.org/10.1097/j.pain.0000000000000895.CrossRefPubMedGoogle Scholar
  5. 5.
    Krakowski I, Theobald S, Balp L, Bonnefoi MP, Chvetzoff G, Collard O, et al. Standards, options, et recommandations: traitements antalgiques médicamenteux des douleurs cancéreuses par excès de nociception chez l’adulte, mise à jours 2002. Paris: Fédération Nationale des Centres de Lutte Contre le Cancer; 2002. http://www.fnclcc.fr Google Scholar
  6. 6.
    Van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain. 2007;132:312–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Garcia B. Prise en charge de la douleur en cancérologie digestive. Post’U. 2011:169–72.Google Scholar
  8. 8.
    Krakowski I, Theobald S, Balp L, Bonnefoi MP, Chvetzoff G, Collard O, et al. Summary version of the standards, options, and recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer. 2003;89(Suppl 1):S67–72.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf. 2005;28(3):227–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Le Dictionnaire Vidal. Paris: Edition du Vidal; 2011.Google Scholar
  11. 11.
    Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood. 2001;97(12):3846–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Nuttall SL, Williams J, Kendall MJ. Does paracetamol cause asthma? J Clin Pharm Ther. 2003;28(4):251–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Graham GG, Scott KF, Day RO. Tolérance du paracétamol. Drugs. 2003;63(2):43–6.PubMedGoogle Scholar
  14. 14.
    Prescriptions et surveillance des antiinflammatoires stéroïdiens et non stéroïdiens. Support de cours. Université Médicale Virtuelle Francophone 2008–2009. http://sist.education.gov.mg/UMVFmiroir/campus-cours-c/rhumato25/site/html/cours.pdf.
  15. 15.
    Sunshine A, Olson NZ. Non-narcotic analgesics. In: Wall PD, Melzack R, editors. Textbook of pain. 2nd ed. New York: Churchill Livingstone; 1989. p. 670–85.Google Scholar
  16. 16.
    Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992;26:234–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nefopam: review of its pharmacological properties and therapeutic efficacy. Drugs. 1980;19:249–67.CrossRefPubMedGoogle Scholar
  18. 18.
    Durrieu G, Olivier P, Bagheri H, Montastruc JL. Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol. 2007;21(5):555–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Pillans PI, Woods DJ. Adverse reactions associated with nefopam. N Z Med J. 1995;108(1008):382–4.PubMedGoogle Scholar
  20. 20.
    Leppert W. Tramadol as an analgesic for mild to moderate cancer pain: review. Pharmacol Rep. 2009;61:978–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs. 1997;53(Suppl 2):18–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Coulombe A, Thiffault R. Le syndrome sérotoninergique secondaire à l’association du tramadol et des inhibiteurs sélectifs du recaptage de la sérotonine. Pharmactuel. 2008;41(1):30–5.Google Scholar
  23. 23.
    Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006;59:1046–51.CrossRefPubMedGoogle Scholar
  24. 24.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Leppert W. Pain management in patients with cancer: focus on opioid analgesics. Curr Pain Headache Rep. 2011;15:271–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9):2542–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76:1283–93.CrossRefPubMedGoogle Scholar
  28. 28.
    De Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manag. 1995;10:378–84.CrossRefGoogle Scholar
  29. 29.
    Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manag. 1996;12:182–9.CrossRefGoogle Scholar
  30. 30.
    Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 1996;67:115–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Ashby MA, Martin P, Jackson KA. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust. 1999;170:68–71.PubMedGoogle Scholar
  32. 32.
    Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527–34.CrossRefPubMedGoogle Scholar
  33. 33.
    McDonald P, Graham P, Clayton M, Buhagiar A, Stuart-Harris R. Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med. 1991;5:323–9.CrossRefGoogle Scholar
  34. 34.
    Drexel H, Dzien A, Spiegel RW, Lang AH, Breier C, Abbrederis K, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain. 1989;36:169–76.CrossRefPubMedGoogle Scholar
  35. 35.
    Derby S, Portenoy RK. Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera E, editors. Topics in palliative care. New York: Oxford University Press; 1997. p. 95–112.Google Scholar
  36. 36.
    Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998;12:375–82.CrossRefPubMedGoogle Scholar
  37. 37.
    Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135–44.CrossRefPubMedGoogle Scholar
  38. 38.
    Sykes NP. Oral naloxone in opioid-associated constipation. Lancet. 1991;337:1475.CrossRefPubMedGoogle Scholar
  39. 39.
    Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther. 1992;52:90–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Chey WD, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387–96.CrossRefPubMedGoogle Scholar
  41. 41.
    Ahmedzai S, Brooks D, The TTS-Fentanyl Comparative Trial Group. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manag. 1997;13:254–61.CrossRefGoogle Scholar
  42. 42.
    Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol. 1998;16:1588–93.CrossRefPubMedGoogle Scholar
  43. 43.
    Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manag. 1998;16:121–4.CrossRefGoogle Scholar
  44. 44.
    Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald RN. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep. 1987;71:67–70.PubMedGoogle Scholar
  45. 45.
    Bruera E, Brenneis C, Paterson AH, MacDonald RN. Narcotics plus methylphenidate (Ritalin) for advanced cancer pain. Am J Nurs. 1988;88:1555–6.PubMedGoogle Scholar
  46. 46.
    Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manag. 1989;4:3–6.CrossRefGoogle Scholar
  47. 47.
    Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992;48:163–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates: a preliminary report. Pain. 1992;50:75–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Wilwerding MB, Loprinzi CL, Mailliard JA, O’Fallon JR, Miser AW, van Haelst C, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer. 1995;3:135–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M, et al. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manag. 1995;10:287–91.CrossRefGoogle Scholar
  51. 51.
    Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain. 1992;49:87–91.CrossRefPubMedGoogle Scholar
  52. 52.
    Organisation Mondiale de la Santé. Traitement de la douleur cancéreuse: complétée par une analyse des problèmes liés à la mise à disposition des opioïdes. Genève: OMS; 1997.Google Scholar
  53. 53.
    Simonnet G, Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport. 2003;14(1):1–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Mercadente S, Lodi F, Sapio M, Calligara M, Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manag. 1995;10:564–8.CrossRefGoogle Scholar
  55. 55.
    Fitzgibbon EJ, Schroder C, Viola R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manag. 2002;23:165–70.CrossRefGoogle Scholar
  56. 56.
    Benitez-Rosario MA, Feria M, Salinas-Martin A. A retrospective comparison of the dose ratio between subcutaneous and oral ketamine. J Pain Symptom Manag. 2003;25:400–1.CrossRefGoogle Scholar
  57. 57.
    Mercadante S. Ketamine in cancer pain: an update. Palliat Med. 1996;10:225–30.PubMedGoogle Scholar
  58. 58.
    Fitzgibbon EJ, Viola R. Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for palliative care unit. J Palliat Med. 2005;8(1):49–57.CrossRefPubMedGoogle Scholar
  59. 59.
    Huot A-M. La kétamine dans le soulagement des douleurs. Pharmactuel. 2006;39(4):229–30.Google Scholar
  60. 60.
    Bauer C, Lahjibi-Paulet H, Somme D, Onody P, Saint Jean O, Gisselbrecht M. Tolerability of an equimolar mix of nitrous oxide and oxygen during painful procedures in very elderly patients. Drugs Aging. 2007;24(6):501–7.CrossRefPubMedGoogle Scholar
  61. 61.
    Onody P, Gil P, Hennequin M. Safety of inhalation of a 50% nitrous oxide/oxygen premix: a prospective survey of 35, 828 administrations. Drug Saf. 2006;29(7):633–40.CrossRefPubMedGoogle Scholar
  62. 62.
    Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109:707–22.CrossRefPubMedGoogle Scholar
  63. 63.
    PRIALT. HAS, Commission de la transparence. 14 mai 2008. www.has-sante.fr.
  64. 64.
    Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain. New drug class. Lancet. 2010;375:1569.CrossRefPubMedGoogle Scholar
  65. 65.
    Staats P. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA. 2003;291:63–70.CrossRefGoogle Scholar
  66. 66.
    Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomised double blind placebo controlled clinical trial. Neuromodulation. 2006;9(2):75–86.CrossRefPubMedGoogle Scholar
  67. 67.
    Rauck RL. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag. 2006;31:393–406.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Supportive Care DepartmentInstitut BergoniéBordeauxFrance

Personalised recommendations